Tracleer (bosentan) is a small molecule pharmaceutical. Bosentan was first approved as Tracleer on 2001-11-20. It is used to treat pulmonary hypertension in the USA. It has been approved in Europe to treat pulmonary hypertension and systemic scleroderma. The pharmaceutical is active against endothelin receptor type B. In addition, it is known to target endothelin-1 receptor. Tracleer's patent is valid until 2027-12-28 (FDA).
|Indication||pulmonary hypertension, systemic scleroderma|
|Drug Class||Endothelin receptor antagonists|